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Research
A decade ago, the landmark studies from the 
Seychelles (Davidson et al. 1998) and Faroe 
islands (Grandjean et al. 1997) were unfold‑
ing and a debate was raging over how much 
risk is associated with methylmercury (MeHg) 
in fish. Both the Seychelles and Faroe studies 
involved populations that have a high per cap‑
ita consumption of fish and MeHg body 
burdens generally higher than in the United 
States (Davidson et al. 1998; Grandjean et al. 
1997). The Seychelles study showed no evi‑
dence of harm, whereas the Faroe study, at 
similar MeHg exposure levels, showed sig‑
nificant neurodevelopmental deficits at birth 
and into the early school years (Axelrad et al. 
2007). Interpretation of these studies by the 
U.S. Environmental Protection Agency (EPA) 
and Agency for Toxic Substances and Disease 
Registry (ATSDR) differed, creating confu‑
sion in federal and state government over 
how to set fish consumption advice (ATSDR 
1999; U.S. EPA 2001). A National Academy 
of Sciences report [National Research Council 
(NRC) 2000] helped resolve the debate by 
concluding that MeHg in fish is an impor‑
tant public health risk and developed a dose–
response analysis for neurodevelopmental 
effects that was subsequently used by the U.S. 
EPA to derive the reference dose (RfD) (U.S. 
EPA 2001). The Seychelles study, although 
still overall a negative (without effects) 
study, recently found some evidence sugges‑
tive of a latent MeHg effect (Davidson et al. 
2006). An ongoing study of a birth cohort in 
Massachussetts shows an association of MeHg 
exposure with neuro  developmental effects at 
lower levels of exposure than in prior studies 
(Oken et al. 2005, 2008).
One might assume that the controversy is 
over. The issue has been through the National 
Academy of Sciences, and public health offi‑
cials now have an RfD on the U.S. EPA’s 
Integrated Risk Information System (IRIS) 
database (U.S. EPA 2001) that can be used 
to set fish consumption limits. Why, then, is 
the subject of fish consumption still as debat‑
able now as it was a decade ago? The answer 
is that the nutrients in fish, especially the fish 
oil omega‑3 fatty acids (FAs) eicosa  pentaenoic 
acid (EPA; C20:5 n‑3) and docosa  hexaenoic 
acid (DHA; C22:6 n‑3) have been increas‑
ingly identified as having public health ben‑
efits. This leads to the concern that avoiding 
fish because of contaminants will eliminate 
the benefits from fish consumption, a concern 
heightened by the fact that the most abun‑
dant natural source of EPA and DHA is fish 
(Racine and Deckelbaum 2007). Balancing 
the risks and benefits of fish consumption has 
become an increasingly important goal of fish 
consumption advisories. However, recent mes‑
sages in the media that emphasize fish benefits 
have created confusion about the need for cau‑
tion (Hobson 2006). In one case, an advocacy 
group recommended that pregnant women 
exceed federal fish consumption guidelines, 
but that group has subsequently been found to 
have dubious funding sources (Couzin 2007). 
On the other hand, warnings about MeHg lev‑
els in fish can provide overly negative messages 
that cause women to completely avoid fish 
(Cohen et al. 2005a; Oken et al. 2003).
In this article we quantitatively address 
key aspects of the fish risk/benefit issue by 
analyzing the health trade‑offs for individual 
fish species. Although MeHg and omega‑3 
FA are both present in fish, species can be 
distinguished based on the relative propor‑
tion of these constituents (Mahaffey et al. 
2007; Stern 2007). The present analysis 
provides a quantitative approach for iden‑
tifying which fish are most beneficial for 
neuro  developmental and cardio  vascular out‑
comes. Our focus is on the potential utility 
of the approach rather than the exact results 
obtained to date, because uncertainties in 
the underlying dose response make the con‑
clusions tentative. Although showing pos‑
sible directions for species‑specific advisories, 
the analysis points to key research areas for 
improving risk/benefit analysis for fish con‑
sumption. The demonstrated approach may 
serve as a model for analyzing fish species, 
contaminants, and end points not included in 
the present analysis.
Evidence of fish consumption effects on 
neurologic and cardio  vascular outcomes. The 
ingestion of fish or fish oils has been associ‑
ated with an array of health benefits, including 
improvement of blood lipid profiles, decreased 
risk of heart disease, and lowered blood pres‑
sure [Institute of Medicine (IOM) 2006; 
Mozaffarian and Rimm 2006], improvement in 
rheumatoid arthritis (Kremer 2000), enhanced 
eye and brain develop  ment in early life (Fleith 
and Clandinin 2005), prevention of macular 
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degeneration (SanGiovanni et al. 2007), lower 
risk of colitis (Hudert et al. 2006) and type 2 
diabetes (Barre 2007), and improvement in 
neurologic and psychological disorders such 
as depression, schizophrenia, and Parkinson 
disease (Calon and Cole 2007). Diets rich in 
omega‑3 FA increase the ratio of omega‑3 to 
omega‑6 (primarily from vegetable sources) in 
cell membranes. This, as well as a host of related 
effects on lipid chemistry, leads to a generalized 
anti  oxidant, anti‑inflammatory effect that has 
documented benefits in neural tissues, vascu‑
lar endothelium, and cardiac muscle (antiar‑
rhythmic effect) (Connor 2000; Farooqui et al. 
2007; Massaro et al. 2006; Mozaffarian and 
Rimm 2006; von Schacky 2006).
The purported benefits of fish oil omega‑3 
FA are perhaps best documented for car‑
diovascular end points and enhanced brain 
develop  ment. It is noteworthy that MeHg 
also has toxic effects in these areas. Therefore, 
the present analysis focuses on fish consump‑
tion risks and benefits on these end points. 
The following sections provide a brief review 
of pertinent literature in these areas as back‑
ground for our quantitative species‑specific 
risk/benefit analysis.
Fish and omega-3 FA effects on cardiovas-
cular end points. Recent reviews of the cardio‑
vascular benefits from fish and fish oils have 
focused on mortality from coronary heart 
disease (CHD; IOM 2006; Mozaffarian and 
Rimm 2006; von Schacky 2007). Evidence 
from a combination of 20 different prospec‑
tive cohort studies and clinical trials has 
shown a consistent decline in CHD mortal‑
ity with increasing omega‑3 FA intake (EPA 
+ DHA) with an apparent saturation of this 
benefit at intakes > 250 mg/day (Mozaffarian 
and Rimm 2006). Below an ingestion rate of 
250 mg/day, there was a 14.6% decrease in 
CHD mortality per 100 mg/day omega‑3 FA 
ingested (95% confidence interval, 8–21% 
reduction). CHD benefits were strongest for 
oily fish such as salmon, herring, and sardines 
relative to leaner fish (cod, catfish, halibut). 
Although the weight of evidence supports a 
cardiovascular health benefit from fish oils, 
not all analyses have found this to be the case 
(Hooper et al. 2006).
The meaning of the saturation of ben‑
efit in the Mozaffarian and Rimm (2006) 
pooled analysis is unclear because it contains 
studies in which omega‑3 FA ingestion was 
from fish in some cases and from omega‑3 FA 
supplements in others, with this not clearly 
segregated in their analysis. Saturation of ben‑
efit above 250 mg omega‑3 FA intake per 
day may not be an actual plateau, because as 
fish ingestion increases, so does the intake of 
MeHg. The toxicity of MeHg on the same 
cardiovascular end point may cause a net lev‑
eling off of the benefit. Separate evaluation 
of omega‑3 FA supplementation studies is 
needed to refine the analysis, but in general, 
there are fewer of these studies and they were 
not designed to evaluate dose response (Konig 
et al. 2005). In one particular case, supple‑
mentation of the diet of Japanese adults who 
have cardiovascular disease with 1.8 g/day 
EPA yielded a measureable benefit on CHD 
mortality (von Schacky 2007). Given the 
high level of fish consumption and therefore 
the high background of omega‑3 FA intake 
in this population, the added benefit from 
supplemental fish oil suggests that the benefit 
does not saturate. If this is true, the appar‑
ent saturation reported by Mozaffarian and 
Rimm (2006) may in fact reflect the counter‑
balancing effect of MeHg. Additional research 
in this area is needed.
Fish oil may also have benefits on a 
variety of other cardiovascular end points, 
including decreases in nonfatal myocardial 
infarction (MI), ischemic stroke, atrial fibril‑
lation, athero  sclerosis, and congestive heart 
disease (IOM 2006; Mozaffarian and Rimm 
2006; von Schacky 2007). However, the evi‑
dence in these cases is limited and not cur‑
rently suitable for a risk/benefit assessment of 
fish consumption.
MeHg effects on cardiovascular end points. 
MeHg is a risk factor for cardio  vascular disease 
through a variety of mechanisms potentially 
involving pro‑oxidant effects via the genera‑
tion of radical species and the inactivation 
of cellular antioxidant systems such as gluta‑
thione peroxidase and catalase (Guallar et al. 
2002). There is evidence for lipid peroxida‑
tion and elevations of oxidized low‑density 
lipoprotein in association with MeHg expo‑
sure (Andersen and Andersen 1993; Salonen 
et al. 1995). Mechanistic studies indicate that 
MeHg can exert toxic effects on the vascu‑
lar endothelium by depletion of sulfhydryls, 
increased oxidative stress, and activation of 
phospholipases (Hagele et al. 2007; Mazerik 
et al. 2007). Oral dosing of rats with MeHg 
at a daily rate of 0.5 mg/kg for 9 months 
yielded a persistent pressor effect (Wakita 
1987), whereas inorganic mercury has caused 
a variety of adverse effects on cardio  vascular 
function, including increased blood pressure, 
altered heart rate, and decreased heart con‑
tractility (ATSDR 1999). Given that some of 
these effects occurred at relatively low doses 
(< 1 mg/kg/day), this appears to be a sensitive 
target for MeHg’s effects. Human overdose 
with organic or inorganic mercury has also 
produced a variety of adverse effects on the 
heart and blood pressure, and occupational 
exposure to inorganic mercury has been associ‑
ated with hypertension and non  ischemic heart 
disease (ATSDR 1999; Boffetta et al. 2001).
Epidemiologic evidence is generally sup‑
portive of an association between MeHg body 
burden in the general public, primarily from 
fish consumption, and cardiovascular disease 
(Stern 2005). This database is not as robust 
as that supporting the benefits of fish oils on 
CHD, but nevertheless includes substantive 
findings that need to be accounted for in a 
risk/benefit analysis. A prospective study of 
1,014 Finnish men found that those in the 
highest quintile of MeHg exposure (hair mer‑
cury > 2.81 ppm) had an accelerated thick‑
ening of the carotid artery, an indication of 
atherosclerosis (Salonen et al. 2000). Several 
studies provide evidence of increased CHD 
mortality in men in relation to hair or toe‑
nail mercury (Guallar et al. 2002; Rissanen 
et al. 2000; Salonen et al. 1995; Virtanen et al. 
2005). In a case–control study spanning eight 
European countries and Israel, 684 men with 
MI were found to have significantly greater 
toenail mercury than the 724 matched con‑
trols (Guallar et al. 2002). This association 
demonstrated a linear dose response that was 
strengthened when the positive influence of 
the omega‑3 FA DHA was controlled for in 
the model. An earlier study of 1,833 Finnish 
men followed prospectively showed a doubling 
of risk for MI in the highest tertile of exposure 
(hair mercury > 2 ppm) (Salonen et al. 1995). 
A follow‑up of this eastern Finland popula‑
tion continued to show a heightened risk of 
coronary events due to MeHg that was able 
to offset the positive influence of omega‑3 FA 
(Virtanen et al. 2005).
However, several other studies failed to find 
a consistent association between mercury body 
burden and cardiovascular outcomes (Ahlqwist 
et al. 1999; Hallgren et al. 2001; Yoshizawa 
et al. 2002). A study of 1,462 Swedish women 
did not find an association between serum mer‑
cury and MI or stroke, but that study focused 
primarily on mercury exposure via amalgam 
fillings (Ahlqwist et al. 1999). This appears to 
have been a significant source based on the 
strong correlations between serum mercury and 
number of fillings. There was no assessment of 
fish ingestion or attempt to factor out the ben‑
efit of fish oils on the end points measured. 
In another Swedish study, involving 78 men 
and women with MI and 124 controls, red 
blood cell mercury and plasma EPA + DHA 
were both found to be negative predictors of 
MI risk (Hallgren et al. 2001). However, the 
mercury body burden in this population was 
much lower than in the Finnish studies, possi‑
bly too low to have an adverse effect on its own 
and thus more likely served as a marker for 
omega‑3 FA ingestion from fish. Interestingly, 
the subgroup with the highest red blood cell 
mercury and lowest omega‑3 FA levels had an 
elevated odds ratio, but this was not statistically 
significant possibly due to the low number 
(10) in this group. Overall, this study did not 
have sufficient power to detect an independent 
effect of MeHg on MI, especially given the 
low exposures to MeHg in this population. 
Finally, a large prospective study of U.S. health Risk/benefit analysis of fish consumption
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professionals collected toenail mercury data 
from 33,737 men, of whom 470 had an MI 
during the course of follow‑up (Yoshizawa et al. 
2002). The overall analysis showed no differ‑
ence in risk of MI across the quintiles of toenail 
mercury, but also in contrast to other stud‑
ies, there was no demonstrable benefit from 
fish ingestion. Most subjects were dentists, and 
they were over  represented in the highest expo‑
sure groups (40% in the lowest quintile; 84% 
in the upper quintile). The authors reported a 
positive but non  significant association of mer‑
cury with CHD in a sub  analysis that excluded 
dentists. This may indicate that MeHg from 
fish ingestion has a greater influence on car‑
diovascular risk than inorganic mercury from 
dental amalgams. Although speculative, this 
would help explain the negative findings in 
the Swedish women’s study described above 
(Ahlqwist et al. 1999).
Overall, mechanistic evidence and results 
of animal toxicology, human clinical toxicol‑
ogy, and epidemiology studies support the 
notion that MeHg can be a risk factor for car‑
diovascular disease. The strongest epidemiol‑
ogy study in this regard is that of Guallar et al. 
(2002), which provided separate dose–response 
functions for MeHg risk and omega‑3 FA 
benefit for the same cardio  vascular end point. 
Therefore, we used this study as one of the core 
studies for our risk/benefit analysis for cardio‑
vascular end points in men.
Fish and omega-3 FA effects on neuro-
development. Fish oils, and in particular 
DHA, have been associated with a number of 
beneficial effects on neurocognitive and ocu‑
lar function, both in early life and in old age. 
These associations include increased visual 
acuity in newborns (Uauy et al. 2003), better 
scores on neuro  developmental test batteries 
(Daniels et al. 2004; Fleith and Clandinin 
2005; Oken et al. 2005, 2008), and preven‑
tion of a number of neuro  psychiatric dis‑
orders in adults, including attention deficit 
dis  order, Alzheimer disease, schizophrenia, 
and depression (Calon and Cole 2007; Young 
and Conquer 2005). Dietary supplementa‑
tion with DHA prevented a number of 
biochemical changes induced by 1‑methyl‑4‑
phenyl‑1,2,3,6‑tetrahydropyridine (MPTP) 
in a mouse model of Parkinson disease 
(Bousquet et al. 2008). The early‑life evi‑
dence comes from studies in both preterm 
and full‑term infants, with the benefits more 
consistently shown in preterm infants. These 
trials have involved the addition of omega‑3 
FA to infant formula. Part of the impetus 
for the early‑life studies is the finding that 
formula‑fed babies have less plasma and red 
cell DHA than do breast‑fed babies, leading 
to the question of whether formula should be 
supplemented with omega‑3 FA (Fleith and 
Clandinin 2005). The strongest association 
in the fish oil supplementation studies has 
been with the development of vision, particu‑
larly within the first year of life. In addition, 
maternal ingestion of fish has been associated 
with enhanced neurocognitive development 
in ongoing prospective studies (Daniels et al. 
2004; Hibbeln et al. 2007; Oken et al. 2005, 
2008). Other nutrients in fish may contribute 
to the neurodevelopmental benefit. However, 
the fact that this benefit is demonstrable with 
omega‑3 FA supplementation alone indicates 
an important role for this nutrient (Cohen 
et al. 2005b).
The present analysis focuses on the evi‑
dence of a neurodevelopmental benefit from 
maternal fish and omega‑3 FA ingestion 
during pregnancy and, in particular, on one 
study that adjusted for the developmental 
deficits induced by the concomitant ingestion 
of MeHg in the fish (Oken et al. 2005), from 
which it is possible to develop independent 
dose–response relationships for omega‑3 FA 
benefit and MeHg risk on the same neuro‑
developmental end point. Dose–response rela‑
tionships for MeHg and omega‑3 FA effects 
on IQ have also been derived from a syn‑
thesis of the relevant litera  ture (Cohen et al. 
2005a, 2005b, 2005c). These other analyses 
are consistent with the MeHg/omega‑3 FA 
dose responses obtained from the Oken et al. 
(2005) study that we used as the basis for the 
present analysis.
MeHg effects on neurodevelopment. As 
mentioned above, adverse effects of MeHg 
have been observed in studies of maternal 
exposure from fish ingestion in relation to 
post  natal neuro  development. Oken et al. 
(2005) provided a very useful dose response 
for this effect because they corrected for the 
benefit of fish oil ingestion. Several large pro‑
spective studies also demonstrate an adverse 
effect of MeHg, although inconsistencies 
between them led to considerable debate 
during the 1990s (Davidson et al. 1998; 
Grandjean et al. 1997; Kjellstrom et al. 1989). 
The series of reports from the Faroe Islands 
are consistent with results from New Zealand 
in showing an adverse effect of MeHg on 
neuro  development, and this has been judged 
to outweigh the mostly negative findings from 
the Seychelles Islands (NRC 2000; U.S. EPA 
2001). The epidemiology associations are con‑
sistent with an extensive literature in rodents 
and monkeys demonstrating early‑life vul‑
nerability to the neurotoxic effects of MeHg 
(ATSDR 1999).
Methods for Integrated Risk/
Benefit Analysis
We selected studies from the literature 
described above to support an integrated risk/
benefit analysis for adult cardio  vascular and 
in utero neuro  developmental end points on a 
species‑specific basis. Table 1 summarizes the 
dose–response relationships found for omega‑3 
FA and MeHg for common end points: 
cardio  vascular disease in adults (CHD mor‑
tality or first MI) and neurodevelopment in 
6‑month‑old infants [visual recognition mem‑
ory (VRM)]. The adult end points are very 
similar because both are a measure of coronary 
artery health; the CHD end point includes 
fatal MI and sudden death (Mozaffarian and 
Rimm 2006), whereas the first MI is not nec‑
essarily fatal (Guallar et al. 2002). The omega‑3 
FA benefit on this end point was taken directly 
from the reported slope for change in relative 
risk per 100 mg/day intake of EPA + DHA 
(Mozaffarian and Rimm 2006). This dose 
response was not adjusted for the counterveil‑
ing effect of MeHg and so may under  estimate 
the true relationship or suggest a plateau in 
benefit that is in fact an indication of MeHg 
toxicity (see above). We estimated the dose 
response for MeHg effects on MI from Figure 
1A of Guallar et al. (2002) based on the rela‑
tionship between toenail mercury and MI odds 
ratios. We used the DHA‑adjusted slope from 
Guallar et al. (2002) in the present analysis. 
Because the odds ratio is often an over  estimate 
Table 1. Dose–response relationships for key MeHg and omega-3 FA end points.
End point  Agent  Dose response  Comments  References
Adult CHD mortality  Omega-3 FA  14.6% decreased relative risk  Combined data across 20 studies for EPA + DHA intake versus  Mozaffarian and Rimm 2006
      per 100 mg/day     CHD mortality; possible saturation of benefit > 250 mg/day
Adult MI risk  MeHg  23% increased relative risk   Slope adjusted for DHA content of lipid as index of fish oil intake;   Toenail to hair Hg conversion,
      per 1 ppm hair Hg     risk not apparent < 0.51 ppm hair Hg; toenail Hg measured but    Guallar et al. 2002, Ohno 
        converted to ppm in hair    et al. 2007; odds ratio
          conversion to relative risk,
          Zhang and Yu 1998
Infant VRM score  Omega-3 FA  2.0-point increase per 100 mg/day  VRM measured at 6 months in 135 mother–infant pairs; fish oil  Oken et al. 2005
          intake estimated from dietary survey
Infant VRM score  MeHg  7.5-point decrease per 1 ppm   VRM measured at 6 months in 135 mother–infant pairs; direct  Oken et al. 2005
      hair Hg    measurement of maternal hair HgGinsberg and Toal
270  v o l u m e  117 | n u m b e r 2 | February 2009  •  Environmental Health Perspectives
of the relative risk and because the omega‑3 FA 
cardio  vascular benefit was in terms of improved 
relative risk (Mozaffarian and Rimm 2006), 
we converted the Guallar et al. (2002) data 
to relative risk by the equation provided by 
Zhang and Yu (1998). This provides a reason‑
able estimate of relative risk, although a small 
(15%) relative bias is possible with this method 
(McNutt et al. 2003).
This dose response for MeHg effects 
on MI risk has a hair mercury threshold of 
0.51 ppm before any adverse effect is evident 
(Guallar et al. 2002). Although much of the 
population in that study had mercury levels in 
this range and below, there was no clear dose–
response trend until the body burden rose 
above this apparent threshold. The appearance 
of a threshold may be related to measurement 
error and variability in the baseline population 
that obscures a mercury effect below that level. 
If there is a mercury effect on MI at levels 
< 0.51 ppm in hair, the slope may be differ‑
ent than that seen at higher body burdens. 
Therefore, our estimate of mercury MI risk 
includes this threshold but it is a source of 
uncertainty.
Infant VRM is a common end point 
for both omega‑3 FA and MeHg because 
these agents had opposite effects in the 135 
mother–infant pairs evaluated by Oken 
et al. (2005). VRM is a test that evaluates 
an infant’s ability to encode a stimulus (pho‑
tograph) into memory and recognize a new 
stimulus as novel and preferential to the old 
stimulus. This test is predictive of IQ at later 
developmental stages (Rose and Feldman 
1995). The slope for the hair mercury effect 
on VRM score was taken directly from Table 
2 of Oken et al. (2005), who adjusted the 
slope for the amount of fish ingestion. Oken 
et al. (2005) derived the relationship between 
omega‑3 FA intake and VRM score from 
analysis of food survey records and estimation 
of omega‑3 FA content of fish in relation to 
the VRM score for each individual, with cor‑
rection for the inverse association with hair 
mercury (Oken E, personal communication).
We ran the dose–response functions 
shown in Table 1 in Excel spreadsheets 
(Microsoft Corporation, Redmond WA) to 
estimate the effect of one or more fish meals 
on the outcome measure using the following 
risk/benefit equations:
Net risk/benefit for adult CHD =  
  [(omega‑3 FA mg/meal)  
  × (no. meals/week) × (1 week/7 days)  
  × (14.6% lower risk/100 mg omega‑3 FA)]  
  – {[(hair Hg change/fish meal)  
  × (no. meals/week)] – (0.51 ppm hair Hg)}  
  × (23% higher risk/1 ppm hair Hg) 
Net risk/benefit for infant VRM =  
  [(omega‑3 FA mg/meal) × (no. meals/week)   
  × (1 week/7 days)  
  × (2 VRM points/100 mg omega‑3 FA)]  
  – [(hair Hg change per fish meal)  
  × (no. meals/week)  
  × (7.5 VRM points/1 ppm hair Hg)]
Species that yield a positive result from 
these equations have a net benefit, whereas a 
result < 1 signifies an increased risk. 
The omega‑3 FA CHD benefit may satu‑
rate above a certain daily dose, estimated by 
Mozaffarian and Rimm (2006) at 250 mg/
day. However, as described above, this may 
be an artificial saturation due to the increas‑
ing effect of MeHg at higher fish ingestion 
rates and the evidence of no saturation of ben‑
efits in some studies. Therefore, this analysis 
does not include a saturation function for the 
omega‑3 FA benefit.
These risk/benefit equations contain expo‑
sure components based on the number of 
fish meals eaten per week and the MeHg and 
omega‑3 FA content of the fish. These con‑
tents are species specific. Table 2 provides 
estimates for these fish constituents based on 
data from the U.S. Department of Agriculture 
(USDA 2005) for omega‑3 FA (DHA + EPA) 
and from the Food and Drug Administration 
(FDA 2006) for MeHg. There are a variety 
of other sources for omega‑3 FA content of 
fish (e.g., American Heart Association 2008; 
Mozaffarian and Rimm 2006), but these other 
sources tend to either use the USDA data or 
to report very similar results. More extensive 
data for both omega‑3 FA and MeHg content 
of fish (numbers and varieties of fish sampled, 
seasonal and source variation) are needed to 
improve confidence and understand vari‑
ability in this key input data. The list of fish 
chosen for analysis is based on those com‑
monly available in Connecticut markets and 
for which MeHg and omega‑3 FA data are 
available. This approach can be applied to any 
additional species as long as the MeHg and 
fish oil content of these species are known.
We converted the MeHg fish concentra‑
tion (micrograms per gram) to a hair MeHg 
concentration (micrograms per gram) via a 
one‑compartment model that relates MeHg 
intake to hair mercury as used in the U.S. 
EPA’s RfD for mercury (Ginsberg and Toal 
2000; Rice et al. 2003). The assumed meal 
size was 6 oz (170 g) of fish, with other 
parameters used in the model as reported pre‑
viously (e.g., 95% absorption of MeHg in the 
gastro  intestinal tract; MeHg elimination rate 
equals 1.4% of body burden per day). We 
chose a 6‑oz meal size to match the recom‑
mendation used in the joint FDA/U.S. EPA 
seafood consumption advisory of two meals 
per week equivalent to 12 oz of fish (U.S. 
EPA 2004). Use of the Guallar et al. (2002) 
dose response required conversion of toenail 
mercury biomonitoring data to hair mercury. 
We accomplished this with the factor recently 
developed by Ohno et al. (2007) (hair mer‑
cury in micrograms per gram = 2.44 × toenail 
mercury in micrograms per gram). They based 
this factor on the regression slope between 
hair and toenail mercury in 57 women, which 
yielded a strong correlation with only a mod‑
est degree of variability and few outliers. The 
strength of the correlation between hair and 
toenail mercury provides support for the use 
of toenail mercury as biomarker in the Guallar 
et al. (2002) study.
Results
Figures 1–3 show the integrated risk/ben‑
efit analysis for seafood consumption by end 
point and species. Figure 1 shows estimates of 
the influence of MeHg on neuro  development 
at 6 months of age (VRM score) in the 16 fish 
species chosen for analysis. We modeled these 
effects based on long‑term consumption of 
one meal per week for several months, enough 
time to reach steady‑state blood and hair con‑
centrations of MeHg. We assumed that the 
omega‑3 FA benefit requires consistent expo‑
sure over time and that no other fish were 
consumed other than the one meal per week 
of the indicated species. 
Figure 1 shows a range of effects, from a 
large negative effect for swordfish and shark 
to modest positive effects for trout, farmed 
salmon, and herring. The rest of the species 
are in an intermediate zone of rather small 
net effect in the positive or negative direction. 
Canned tuna, both light (primarily skipjack) 
and white (primarily albacore), show negative 
deflections, with white tuna predicted to have 
a 3.7‑fold larger negative impact than light 
tuna. Consumption of more than one meal per 
week on a regular basis would accentuate the 
pattern shown in Figure 1 because there are no 
Table 2. Estimated omega-3 FA and MeHg levels in 
commonly eaten fish.
  Omega-3a  MeHgb 
Fish species  (mg/6 oz)   (µg/g)
Cod, Atlantic  269  0.11
Flounder/sole  852  0.05
Halibut  1,398  0.26
Herring, Atlantic  3,424  0.04
Lobster  1,129  0.24
Pollack  922  0.06
Salmon, Atlantic, farmed  3,658  0.014
Sea bass  1,295  0.27
Shark  1,170  0.99
Shrimp  536  0.01
Swordfish   1,392  0.97
Tilapia  240  0.01
Trout  1,744  0.03
Tuna, canned, light  425  0.12
Tuna, canned, white  1,462  0.35
Tuna, fresh, yellowfin  474  0.325
aOmega-3 FA represents the sum of EPA and DHA. Shark 
data from Mozaffarian and Rimm (2006); other data from 
USDA (2005), bMeHg data from FDA (2006); data for salmon 
reported as fresh/frozen and not distinguished according 
to source.Risk/benefit analysis of fish consumption
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known thresholds or saturation limits to the 
MeHg decrement or omega‑3 FA benefit for 
neuro  development. This means that the inter‑
mediate species in the center of Figure 1 would 
have larger positive and negative deflections the 
more meals ingested per week. This is a possi‑
ble concern for species such as fresh tuna (tuna 
steak), canned white tuna, lobster, and sea bass. 
In contrast, the marginal benefit of species such 
as tilapia, pollack, flounder, and shrimp may 
increase with greater meal frequency. The neg‑
ative impacts of swordfish and shark and the 
beneficial effects of trout, farmed salmon, and 
herring would also be magnified as consump‑
tion of these species goes up. However, the 
presence of other contaminants in species such 
as farm‑raised salmon (Hites et al. 2004) needs 
to be considered when recommending frequent 
fish consumption.
Figure 2 shows the net benefit or risk of 
fish ingestion on CHD mortality and MI. Not 
surprisingly, the pattern across species is simi‑
lar to that shown in Figure 1 because, in our 
framework, the net benefit or risk is contin‑
gent upon the ratio of omega‑3 FA to MeHg 
in the fish, which does not change when 
analyzing different end points. However, the 
results in Figure 2 suggest that the risk/benefit 
ratio is more in the benefit direction for CHD 
mortality compared with VRM score. This can 
be seen by the number of species with positive 
deflections in Figure 2 (13) compared with 
Figure 1 (7), with such commonly eaten foods 
as canned tuna and cod having a beneficial 
influence on the cardio  vascular end point but 
negative influence on the neuro  developmental 
end point. One reason for the greater ben‑
efit of fish consumption on this end point is 
the MeHg threshold built into this equation. 
Species in the central portion of Figure 1 have 
low to intermediate levels of both MeHg and 
omega‑3 FA; these species are at or below the 
MeHg effect threshold, thus allowing their 
modest level of omega‑3 FA to be the primary 
influence. The underlying slope factors are 
also more favorable for a net benefit in the 
case of cardio  vascular risk. However, we esti‑
mated a substantial risk for those whose fish 
ingestion consists of swordfish or shark; the 
negative deflection reflects an approximately 
50% worsening of the relative risk for MI. In 
contrast, we estimated an approximately 75% 
improvement for salmon and herring. These 
effects are magnified for species on either end 
of the spectrum when simulating two 6‑oz 
meals per week for each species (Figure 3). 
Intermediate species show little change at two 
meals per week, an indication that they have 
surpassed the MeHg toxicity threshold with 
this increase in consumption, and this pre‑
vents a further benefit from more omega‑3 FA 
intake. The species‑specific risk/benefit pattern 
did not change when evaluating four meals per 
week (data not shown).
The present risk/benefit analysis allows us 
to tentatively classify these species into cat‑
egories of fish consumption. Table 3 presents 
four consumption categories to illustrate how 
this analytical framework can be used to guide 
advisories. The species‑specific risk/benefit 
rankings were sufficiently different across end 
points to yield slightly different advice for 
those in the neurodevelopmental risk group 
versus the cardiovascular risk group. 
We have tentatively created an unlimited 
category because, for the end points and con‑
stituents analyzed, increasing consumption of 
certain fish was associated with an increasing 
benefit. A caveat is the evidence for a satura‑
tion of the omega‑3 FA cardio  vascular benefit 
Figure 1. Estimated net effect of MeHg and fish oils on neurodevelopment at 6 months of age, one 6-oz fish 
meal per week.
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Figure 2. Estimated net effect of MeHg and fish oils on cardiovascular risk, one 6-oz fish meal per week.
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Figure 3. Estimated net effect of MeHg and fish oils on cardiovascular risk, two 6-oz fish meals per week.
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> 250 mg/day (Mozaffarian and Rimm 2006), 
but as described above, saturation of the ben‑
efit is speculative for cardiovascular risk and 
is not evident in the limited analyses available 
for neurodevelopmental risk (Hibbeln et al. 
2007; Oken et al. 2005, 2008). However, 
because of persistent organochlorine con‑
taminants in certain species such as farmed 
salmon, one must consider consumption lim‑
its based on cancer risk or other end points 
(Foran et al. 2005). Data for such contami‑
nants should be analyzed to make sure that 
unlimited consumption of these species is 
appropriate.
Only a few species are in the twice‑per‑
week consumption category, which is the 
general seafood advice from the FDA (2004). 
This is because the largest category is unlim‑
ited consumption, containing seven spe‑
cies for the neuro  developmental risk group. 
Unlimited consumption is taken to mean one 
6‑oz meal per day. Figures 1–3 show these 
species to be associated with net beneficial 
effects, regardless of the number of meals per 
week. Fish were placed in this category if they 
have a net beneficial effect and also if the RfD 
for mercury (0.1 µg/kg/day) is not exceeded 
from daily fish ingestion. For the neurode‑
velopmental risk group, cod and canned 
light tuna have a slight negative deflection in 
Figure 1, but were placed in the twice weekly 
category because when eaten at this frequency 
they provide less MeHg than the neurodevel‑
opmental RfD and are unlikely to be a signifi‑
cant risk, given the various uncertainties and 
the fact that there are other nutrients in fish. 
We included five species in the once weekly 
category (canned white tuna, tuna steak, 
halibut, sea bass, lobster). Although we esti‑
mated them to yield a net risk at one meal per 
week (Figure 1), they are also at or below the 
neuro  developmental RfD at this frequency. 
Swordfish and shark have considerably more 
MeHg, and are estimated to have a much 
greater net risk and so are in the “do not eat” 
category. Of the 16 species analyzed, none fit 
into a one meal per month category, although 
that may be appropriate for other fish.
For the cardiovascular risk group, unlim‑
ited consumption appears to be appropriate 
for nine species, and potentially several more 
(Figures 2, 3). However, we downgraded 
canned white tuna, halibut, sea bass, and lob‑
ster to two meals per month because of con‑
cerns for neurologic effects. There is no MeHg 
RfD relevant for the general population, but a 
number of states have used a 3‑fold higher 
target dose (0.3 µg/kg/day) given the likely 
differences in sensitivity for neurologic effects 
between early life and adults (McCann 2005); 
this target dose is the same as the IRIS RfD 
for inorganic mercury salts (U.S. EPA 1995). 
Thus, we placed species in the twice weekly 
category to keep MeHg exposure below the 
target dose for the general public to prevent 
neurologic effects. Tuna steak was placed in 
the once weekly category to limit the risk as 
estimated in Figures 2 and 3, which is very 
small at once per week. We estimated sword‑
fish and shark to have a substantial net risk, 
even at one meal per month; thus, they are in 
the “do not eat” category.
Discussion
This analysis presents a first attempt at a 
model that can be refined in the future as 
more data become available on cardio  vascular 
and neuro  developmental risks of MeHg, 
and the health benefits of consuming fish 
and fish oils. Although we acknowledge that 
there are limitations in the data used to derive 
this model, there appears to be an obvious 
utility to this approach. Public health offi‑
cials need to weigh the positive and negative 
aspects of particular fish species when craft‑
ing advisories, but to date, there is no well‑
accepted, objective method to do this. Using 
this model, we have placed species commonly 
available in Connecticut into four consump‑
tion categories to illustrate the potential util‑
ity of the model. These consumption rates can 
be used as a point of comparison with rates 
being recommended by the FDA, the U.S. 
EPA, and various medical and public health 
authorities, after recognizing the limitations 
of the present analysis. 
We considered the influence of fish con‑
sumption on end points that are among the 
most sensitive for the beneficial effects of 
omega‑3 FA and the toxicity of MeHg. The 
analysis addresses two completely different 
groups (adults and the fetus) and encompasses 
16 different species, yet it is simplistic in only 
assessing two factors regarding fish ingestion 
that may influence these end points. Other 
nutrients such as protein, selenium, iron, and 
iodide and other contaminants such as poly‑
chlorinated biphenyls, persistent pesticides, 
and dioxins (Bocio et al. 2007; Hites et al. 
2004) may also be contained in these species. 
We chose constituents (omega‑3 FA, MeHg) 
that have a mechanistic basis for influenc‑
ing cardiovascular and neuro  developmental 
outcomes and have actually been shown to do 
so in a variety of animal and human studies 
(Cohen et al. 2005a; IOM 2006; Mozaffarian 
and Rimm 2006). However, the potential 
importance of other constituents and end 
points creates uncertainty regarding the over‑
all health implications of fish consumption.
It is important to recognize that fish 
ingestion has shown a beneficial effect on 
neuro  developmental and cardiac outcomes 
in a number of studies (Daniels et al. 2004; 
Hibbeln et al. 2007; IOM 2006; Mozaffarian 
and Rimm 2006; Oken et al. 2005). Therefore, 
an important public health message is that fish 
are a key dietary component. However, this 
can also be incorrectly interpreted to mean 
that, despite MeHg contamination, fish inges‑
tion is a positive influence and consumption 
limits are unnecessary (Hibbeln et al. 2007). 
Results from general population studies are 
likely a reflection of the types of fish eaten. If 
the studied population ingested more beneficial 
fish (Figures 1–3), this can create the appear‑
ance of a generalizable positive association in 
the absence of information on the actual spe‑
cies consumed. However, the present analy‑
sis and those of others (Guallar et al. 2002; 
Mahaffey et al. 2007; Oken et al. 2005, 2008; 
Stern 2007) point out the importance of look‑
ing at individual species because the risk/ben‑
efit ratio may vary considerably across species. 
A species‑by‑species approach to consumption 
advisories is particularly meaningful given that 
many people have favorite fish they eat most 
often. The goal of the species‑specific approach 
is to encourage people to eat from a variety of 
fish, focusing on the most beneficial species.
Our analysis is supportive of the federal 
advisory (FDA 2004; U.S. EPA 2004) in 
showing that certain species should not be 
eaten by women of child  bearing age (sword‑
fish, shark; federal advisory also lists king 
mackerel and tilefish). In addition, we provide 
Table 3. Tentative fish consumption categories for the 16 species analyzed in the present risk/benefit assess-
ment (based on 6-oz meal size).
Risk group  Consumption category  Fish species
Neurodevelopmentala  Unlimited (pending evaluation of other   Tilapia, pollack, flounder, shrimp,
    contaminants)b    trout, herring, salmon 
  Twice per week  Canned light tuna, cod
  Once per week  Canned white tuna, tuna steak, 
      halibut, sea bass, lobster
  Do not eat  Swordfish, shark 
Cardiovascularc  Unlimited (pending other contaminants)c  Tilapia, pollack, flounder, shrimp, 
      trout, herring, salmon, canned 
      light tuna, cod
  Twice per week  Canned white tuna, halibut, sea 
      bass, lobster 
  Once per week  Tuna steak
  Do not eat  Swordfish, shark
aPregnant women, women of childbearing age, nursing mothers, young children. bUnlimited taken to mean daily con-
sumption. cGeneral adult population. Risk/benefit analysis of fish consumption
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risk/benefit support for separate two meal 
and one meal per week categories. The federal 
advisory generally recommends two 6‑oz sea‑
food meals per week but does specifically limit 
canned white tuna to one meal per week. The 
present analysis goes beyond that to list other 
species that are candidates for the once weekly 
category. Further, we provide a list of species 
that may potentially be safely consumed at 
greater than the meal frequency recommended 
by the federal advisory, on the basis of neuro‑
developmental and cardio  vascular risks, with‑
out taking into account other contaminants 
and end points of potential concern.
This assignment of consumption advice 
for individual species is tentative given the 
limitations inherent in the present analysis. 
The dose–response relationships for the risks 
and benefits of these components (Table 1) 
are supported by the available data but do 
contain uncertainties. The omega‑3 FA ben‑
efit for acute cardio  vascular risk has been doc‑
umented in numerous epidemiology studies, 
and the dose response shown in Table 1 is a 
synthesis of 20 different studies (Mozaffarian 
and Rimm 2006). However, many of these 
studies involved fish consumption rather than 
omega‑3 FA supplementation; therefore, the 
effect of a single nutrient (omega‑3 FA) is 
uncertain, given that other nutrients in fish 
may have contributed to the observed ben‑
efit. Although this remains an uncertainty, 
omega‑3 FA is a well‑established benefit for 
cardio  vascular risk and is the main fish nutri‑
ent for which dose–response relationships 
have been reported. Therefore, this is the most 
feasible approach at the current time. This 
is not an area of possible under  estimation 
of fish benefits. The benefits attributed to 
omega‑3 FA in the fish consumption stud‑
ies come from all nutrients, not just the fish 
oils, because we made no attempt to separate 
out these other benefits. From this perspec‑
tive, the omega‑3 FA dose–response functions 
developed in the present analysis will tend to 
capture the overall benefit of fish consump‑
tion, except for the limited extent to which 
studies of fish oil supplements contribute to 
the supporting database.
MeHg effects on heart function and blood 
vessels have been reported in animal stud‑
ies, cell cultures, and two large epidemiology 
studies (ATSDR 1999; Guallar et al. 2002; 
Mazerik et al. 2007; Rissanen et al. 2000; 
Salonen et al. 1995, 2000; Virtanen et al. 
2005). This includes a series of four reports 
from a group of men in eastern Finland 
whose diet was enriched in fish that are low 
in omega‑3 FA and relatively high in MeHg 
(Guallar et al. 2002; Rissanen et al. 2000; 
Salonen et al. 1995; Virtanen et al. 2005). 
This cohort provides a good opportunity to 
document an MeHg effect without much 
compensation by dietary omega‑3 FA. Guallar 
et al. (2002) studied a different population of 
men from across Europe and Israel in whom 
MeHg exposure varied substantially based 
on country of residence and sources of fish 
intake. The association of MeHg with increas‑
ing cardio  vascular risk was evident even with‑
out correction for DHA exposure, but the 
association was strengthened once DHA was 
considered. These findings provided a rea‑
sonable dose response for the present study 
(Table 1) despite the fact that several stud‑
ies have not shown such an association with 
inorganic mercury or MeHg (Ahlqwist et al. 
1999; Hallgren et al. 2001; Yoshizawa et al. 
2002). One of these was primarily a study of 
occupational exposure to elemental mercury 
from dental amalgam (Yoshizawa et al. 2002), 
another was in Swedish women rather than 
men and also appears to have amalgam as a 
primary source of mercury (Ahlqwist et al. 
1999), and the more recent Swedish study 
had too few subjects with elevated mercury 
exposure (Hallgren et al. 2001). Therefore, 
these studies are not substantial counter‑
weights to the positive findings in European 
men described above. However, these posi‑
tive findings are limited in coming from only 
two data sets, eastern Finland and the Guallar 
et al. (2002) results, with a useful dose–
response analysis available only in the latter 
case. It is possible that reanalysis of the east‑
ern Finland data could further support this 
dose response, because Salonen et al. (1995) 
found an odds ratio (2.0) for elevated hair 
mercury (≥ 2 ppm) similar to that found by 
Guallar et al. (2002). Further exploration of 
MeHg effects on cardiovascular risk is critical 
for establishing fish consumption advice that 
is adequately protective for this end point.
Regarding the neurodevelopmental 
dose response shown in Table 1, both the 
omega‑3 FA benefit and MeHg risk factors 
were derived by Oken et al. (2005) from an 
analysis of VRM scores in 6‑month‑old chil‑
dren. The group in that study which most 
clearly showed the MeHg effect was small 
(high hair mercury, low fish intake; n = 12). 
However, other data corroborate this dose 
response. Figure 4 shows our comparison 
of data from Oken et al. (2005) with dose–
response factors for a related end point, IQ, as 
synthesized from several studies (Cohen et al. 
2005a, 2005b, 2005c). The ratio of omega‑3 
FA benefits to MeHg risks is similar across 
these studies, with the dose response for IQ 
somewhat less in the benefit direction than 
the one we used based on VRM. Therefore, it 
is unlikely that we are under  estimating the net 
fish benefit on neuro  development by using 
the Oken et al. (2005) analysis as our basis. A 
recent follow‑up with this group of mother–
child pairs found neuro  developmental evi‑
dence of fish ingestion bene  fits and MeHg 
risks extending out to 3 years of age (Oken 
et al. 2008). There was evidence of a beneficial 
influence of omega‑3 FAs on these outcomes, 
but this did not attain statistical significance, 
possibly due to the uncertainties in calculat‑
ing omega‑3 FA intake from diaries of fish 
consumption. The role of fish oils and other 
fish nutrients in assisting brain development 
needs to be a continuing research focus.
Our analysis is limited in that we assessed 
each fish species in isolation from consump‑
tion of any other fish. People generally eat 
a variety of fish, although some may have a 
strong preference for one particular species. 
A robust analysis of food dietary patterns can 
be used to assess what fish the U.S. popula‑
tion eats (Carrington and Bolger 2002) and 
how this influences the risk/benefit equation 
across average or upper‑bound consumers. 
Other variabilities not expressed in our analy‑
sis are important to explore and build into 
more refined analyses: the variability in fish 
concentrations in omega‑3 FA and MeHg, 
the variability in the toxico  kinetics of MeHg, 
and the variability in response functions for 
omega‑3 FA and MeHg. Although the pres‑
ent analysis does not address population risk, 
it provides a useful framework for analyzing 
species‑specific risks and benefits that need to 
be considered when deriving fish advisories. 
This is critical because a number of states, 
including Connecticut, are evaluating ways to 
highlight beneficial fish and discourage con‑
sumption of the riskier species.
Several other analyses of the risks and ben‑
efits of fish consumption have been published 
that range from purely qualitative to more 
quantitative estimates of net risk or bene  fit. 
The IOM (2006) provided a qualitative sum‑
mary and recommended that fish be included 
in the diet but within federal consumption 
guidelines. Adults at risk for cardio  vascular 
disease are recommended to eat two 3‑oz 
meals per week as a preventative measure. 
Above this consumption rate, the IOM rec‑
ommends diversifying the fish intake to mini‑
mize the chance of excessive MeHg exposure 
from particular fish sources. Mozaffarian and 
Figure 4. Comparison of estimated effect sizes for 
MeHg and omega-3 FAs on IQ (Cohen et al. 2005a) 
and VRM (Oken et al. 2005). Scale for IQ points is 
multiplied by 10 to adjust size of bars for easy view-
ing relative to VRM score.
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Rimm (2006) performed a more quantitative 
assessment of dose–response relationships for 
fish oil benefits on cardiovascular outcomes, 
but they did not provide a quantitative assess‑
ment of MeHg risks. Their risk/benefit assess‑
ment was mostly qualitative and concluded 
that consuming one to two servings of fish 
per week is beneficial in adults and in women 
of child  bearing age, although the latter group 
should be wary of a few high MeHg species. 
In an analysis of seafood available in New 
Jersey markets, Burger et al. (2005) focused 
on cost and health considera  tions but not 
the benefits of omega‑3 FA. They found that 
flounder was the most economical species that 
is low in MeHg. Cohen et al. (2005a) used 
quality‑adjusted life years (QALYs) to put 
the MeHg risks to cognitive development on 
a common scale with fish benefits for CHD 
mortality, stroke prevention, and DHA bene‑
fits for neuro  development. Their analysis 
looked at how consumption patterns may 
shift in response to fish advisories and found a 
net benefit if advisories are properly followed 
but substantial health risks if advisories lead 
to unnecessary decreases in fish consump‑
tion. Ponce et al. (2000) also used QALYs 
to contrast MeHg neurodevelopmental risk 
with fish oil cardiovascular benefits. Their 
article had the drawback of mixing different 
end points and receptor types (early life and 
adult) into a single analysis. Domingo et al. 
(2007a, 2007b) provided data on omega‑3 FA 
and contaminant levels in 14 species sampled 
from fish markets in Catalonia, Spain. They 
analyzed whether certain dietary patterns 
would result in contaminant intakes above 
tolerable daily intakes and whether omega‑3 
FA intakes were adequate with respect to rec‑
ommendations of international heart associa‑
tions. In a somewhat similar vein, Foran et al. 
(2005) quantitatively assessed the risks and 
benefits of farmed and wild salmon consump‑
tion with benefits entered into the equation as 
the omega‑3 FA content of the meal and the 
risk assessed based on the cumulative cancer 
or non  cancer risk of the contaminants (target 
cancer risk, 1 in 10–5, target non  cancer risk 
of unity). Their analysis found that farmed 
salmon should be limited, from less than 
one meal per week to three meals per week 
depending on source, to meet the World 
Health Organization (1998) target dose for 
dioxin equivalents (1 pg/kg/day), with farmed 
salmon from European sources generally on 
the low end of this consumption advice. These 
frequencies were still associated with elevated 
cancer risk, although they also contained sub‑
stantial omega‑3 FA benefit. It is important to 
keep in mind that trace levels of carcinogens 
are in many foods, so the relative risk/benefit 
ratio of a source such as salmon should ideally 
be compared against other protein sources 
(e.g., meat, dairy, vegetarian sources) if cancer 
is a critical end point. Along these lines, the 
levels of dioxins found in some farmed salmon 
are greater than what is typically available 
from other protein sources. The Connecticut 
Department of Public Health’s latest seafood 
advisory is for no more than one meal per 
week of farmed salmon on this basis.
It may be theoretically possible to obtain 
omega‑3 FA benefits and avoid some of the 
contaminant issues by taking fish oil supple‑
ments. Other foods that are fortified with 
omega‑3 FA, such as eggs and milk, can be 
an additional source. For example, chickens 
fed diets containing ground flaxseed lay eggs 
that are enriched in omega‑3 FA (~ 500 mg/
egg), although most of this is in the form of 
α‑linolenic acid, which has less evidence for 
neuro  developmental and cardiovascular ben‑
efits compared with fish oils (FDA 2005). 
Another form of omega‑3 FA fortification of 
eggs has been developed that involves sup‑
plementation of the hen’s diet with marine 
microalgae, a source reportedly rich in DHA 
(150 mg/egg). Publicly available test data 
regarding the omega‑3 FA content of these 
supplemented foods are needed to understand 
their potential benefit. Another consideration 
is that replacement of fish with supplements or 
fortified eggs will not necessarily provide other 
nutrients that fish offer (e.g., iron, selenium, 
iodide). These nutrients are not being analyzed 
in present risk/benefit analyses but they may 
be part of the benefit being attributed to fish‑
oil ingestion. In general, nutrition authori‑
ties recommend obtaining nutrients from 
the whole food rather than from extracted or 
chemically synthesized components. Finally, 
omega‑3 FA supplements are not regulated 
by the FDA, so label accuracy, quality con‑
trol, and contaminant testing may be issues. 
Clearly, the beneficial effects of omega‑3 FAs 
on cardiovascular and neurodevelopmental 
outcomes need to be further explored in rela‑
tion to the overall benefits of fish consump‑
tion to refine species‑specific advice and to 
make recommendations about the utility of 
fish oil supplements.
In contrast to previous risk/benefit analy‑
ses, the present study is the first to provide an 
integrated analysis for MeHg and omega‑3 
FA that uses dose–response relationships on 
common end points and that evaluates the 
net effect on a species‑by‑species basis. This 
approach and the resulting consumption cat‑
egories illustrate a framework that should be 
helpful in establishing advisories for a wide 
variety of commercially available and locally 
caught fish, assuming that the requisite MeHg 
and omega‑3 FA data are available. We believe 
this can help resolve the confusion that cur‑
rently exists regarding fish consumption and 
yield a message that focuses on the most ben‑
eficial fish choices without eliciting fear over 
the dangers of MeHg. Currently, there are 
numerous uncertainties regarding additional 
contaminants, nutrients, end points, under‑
lying dose–response functions, and compari‑
sons with other protein sources. These factors 
would require a more data intensive and com‑
plex analysis, but this is an important direction 
for the future (Domingo et al. 2007b; Foran 
et al. 2005).
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